BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21538055)

  • 1. β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis.
    Drebber U; Madeja M; Odenthal M; Wedemeyer I; Mönig SP; Brabender J; Bollschweiler E; Hölscher AH; Schneider PM; Dienes HP; Vallböhmer D
    Int J Colorectal Dis; 2011 Sep; 26(9):1127-34. PubMed ID: 21538055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.
    Grimminger PP; Brabender J; Warnecke-Eberz U; Narumiya K; Wandhöfer C; Drebber U; Bollschweiler E; Hölscher AH; Metzger R; Vallböhmer D
    J Surg Res; 2010 Nov; 164(1):e61-6. PubMed ID: 20863523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer.
    Bhangu A; Wood G; Brown G; Darzi A; Tekkis P; Goldin R
    Colorectal Dis; 2014 Apr; 16(4):O133-43. PubMed ID: 24617665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of histological regression grading systems in the neoadjuvant therapy of rectal cancer: do they have prognostic impact?
    Vallböhmer D; Bollschweiler E; Brabender J; Wedemeyer I; Grimminger PP; Metzger R; Schröder W; Gutschow C; Hölscher AH; Drebber U
    Int J Colorectal Dis; 2012 Oct; 27(10):1295-301. PubMed ID: 22614681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of nuclear β-catenin in rectal adenocarcinoma is associated with radioresistance.
    Wang L; Zhang XM; Li Z; Liu XJ; Chai J; Zhang GY; Cheng YF
    World J Gastroenterol; 2013 Oct; 19(40):6876-82. PubMed ID: 24187464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of body mass index and nuclear β-catenin on survival in locally advanced rectal cancer treated with preoperative radiochemotherapy.
    Gomez-Millan J; Queipo MI; Del Mar Delgado M; Perez-Villa L; Roman A; De la Portilla F; Torres E; De Luque V; Bayo E; Medina JA
    J Surg Oncol; 2017 Mar; 115(3):301-306. PubMed ID: 28335081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
    Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.
    Miyazono F; Metzger R; Warnecke-Eberz U; Baldus SE; Brabender J; Bollschweiler E; Doerfler W; Mueller RP; Dienes HP; Aikou T; Hoelscher AH; Schneider PM
    Br J Cancer; 2004 Aug; 91(4):666-72. PubMed ID: 15213712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 as a limited predictor of the therapeutic response to neoadjuvant therapy in locally advanced rectal cancer.
    Kwon MJ; Soh JS; Lim SW; Kang HS; Lim H
    Pathol Res Pract; 2019 May; 215(5):910-917. PubMed ID: 30772061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
    Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of growth pattern and tumor regression identifies a high-risk group in neoadjuvant treated rectal cancer patients.
    Jessberger J; Erlenbach-Wünsch K; Posselt R; Haderlein M; Agaimy A; Fietkau R; Hartmann A; Distel L
    J Dig Dis; 2017 May; 18(5):283-291. PubMed ID: 28342240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: a potential biomarker predictive of metastasis.
    Yao YF; Du CZ; Chen N; Chen P; Gu J
    Dis Colon Rectum; 2014 May; 57(5):602-7. PubMed ID: 24819100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
    Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
    BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Becker H; Baretton GB; Aust DE
    World J Gastroenterol; 2008 Feb; 14(7):1060-6. PubMed ID: 18286688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
    Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.
    Schwaab J; Horisberger K; Ströbel P; Bohn B; Gencer D; Kähler G; Kienle P; Post S; Wenz F; Hofmann WK; Hofheinz RD; Erben P
    BMC Cancer; 2011 Aug; 11():363. PubMed ID: 21854597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High EREG Expression Is Predictive of Better Outcomes in Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.
    Lin CY; Hsieh PL; Chou CL; Yang CC; Lee SW; Tian YF; Shiue YL; Li WS
    Oncology; 2020; 98(8):549-557. PubMed ID: 32408308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.